NCT05939648View on ClinicalTrials.gov

A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

450

Participants

Timeline

Start Date

October 9, 2023

Primary Completion Date

November 30, 2023

Study Completion Date

December 30, 2024

Conditions
SARS-CoV-2
Interventions
BIOLOGICAL

SARS-CoV-2 Bivalent mRNA Vaccine

100 μg /1.0 mL/dose, slightly milky white and clear liquid, intramuscular injection into the lateral deltoid muscle of the upper arm.

OTHER

Saline

100 μg /1.0 mL/dose, intramuscular injection into the lateral deltoid muscle of the upper arm.

Trial Locations (1)

Unknown

Chuanmiao Liu, Bengbu

All Listed Sponsors
collaborator

Ningbo Rongan Biological Pharmaceutical Co., Ltd.

INDUSTRY

lead

AIM Vaccine Co., Ltd.

INDUSTRY

NCT05939648 - A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021) | Biotech Hunter | Biotech Hunter